Anidulafungin Vicuron

IDrugs

Volumn 6, Issue 10, 2003, Pages 980-986

  Martin Mazuelos, Estrella ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BETA GLUCAN SYNTHESIS INHIBITOR; AMINOTRANSFERASE; AMPHOTERICIN; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CYCLOSPORIN; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; GLUCOCORTICOID; ITRACONAZOLE; LY 329960; LY 333006; MICAFUNGIN; NIKKOMYCIN Z; RAVUCONAZOLE; STEROID; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPERGILLOSIS; ATAXIA; BREATHING DISORDER; CLINICAL TRIAL; DEHYDRATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG TOLERABILITY; EPIGASTRIC PAIN; FUNGAL STRAIN; HEADACHE; HUMAN; IMMOBILIZATION; LETHARGY; MAXIMUM TOLERATED DOSE; MYCOSIS; NAUSEA; NONHUMAN; PHLEBITIS; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA;

ANIMALS; ANTIBIOTICS, ANTIFUNGAL; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HUMANS; PEPTIDES, CYCLIC;

EID: 0142214407     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. 163503 LY303366 comparison of activity in murine models of Aspergillus infection. Raab P, Zeckner D, Boyll B, Boylan C, Current W ICAAC 1994 34 Abs F167
2. 163504 LY303366 activity in a rat mucocutaneous vaginal candidiasis model. Zeckner D, Butler T, Boylan CJ, Boyll B, Raab P, Current W ICAAC 1994 34 F169
3. 167942 LY303366 activity in a murine systemic candidiasis model. Zeckner D, Butler T, Boylan CJ, Boyll B, Lin Y, Raab P ICAAC 1993 33 Abs 365
4. 167944 Anti-pneumocystis activity of LY 3030366 and other echinocandin B analogues. Current WL, Boylan CJ, Raab PP ICAAC 1993 33 Abs 368
5. 167985 LY303366 activity against systemic aspergillosis and histoplasmosis in murine models. Zeckner D, Butler T, Boylan C, Boyll B, Lin Y, Raab P, Schmidtke J, Current W 1993 33 Abs 369
6. 187526 Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): Structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB. Debono M, Turner WW, LaGrandeur L, Burkhardt FJ, Nissen JS, Nichols KK, Rodriguez MJ, Zweifel MJ, Zeckner DJ, Gordee RS, Tang, Parr TR Jr J Med Chem 1995 38 17 3271-3281
7. 187895 In vitro evaluation of LY3030366 against Candida species clinical isolates and evaluation of efficacy in a murine model of systemic candidiasis. Zeckner D, Butler T, Boylan CJ, Watson P, Current W ICAAC 1995 35 Abs F98
8. 191957 Compounds active against cell walls of medically important fungi. Hector FR Clin Microbiol Rev 1993 6 1 1-21
9. 248886 In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366 and other antifungal agents. Pfaller MA, Messer SA, Coffmann S Antimicrob Agents Chemother 1997 41 4 763-766
10. 248955 In vitro activity of a new semisynthetic echinocandin, LY303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis and Aspergillus species. Zhanel GG, Karlowsky JA, Harding GA, Balko TV, Zelenitsky SA, Friesen M, Kabani A, Turik M, Hoban DJ Antimicrob Agents Chemother 1997 41 4 863-865
11. 251308 In vitro activity of a new echinocandin, LY-303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Uzun O, Kocagoz S, Cetinkaya Y, Arikan S, Unal S Antimicrob Agents Chemother 1997 41 5 1156-1157
12. 278170 In vitro kill curves of a new semisynthetic echinocandin LY303366, against fluconazole sensitive and resistant Candida species. Karlowsky JA, Harding GA, Zelenitsky SA, Hoban DJ, Kabani A, Balko TV, Turik M, Zhanel GG Antimicrob Agents Chemother 1997 41 11 2576-2578
13. 278179 Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Krishnarao TV, Galgiani JN Antimicrob Agents Chemother 1997 41 9 1957-1960
14. 278181 Echinocandins and pneumocandins - A new class with a novel mode of action. Denning DW J Antimicrob Chemother 1997 40 5 611-614
15. 301927 Efficacy of LY 303366 against amphotericin B susceptible and resistant-aspergillus fumigatus in a murine model invasive of aspergillosis. Verweij PE, Oakley KL, Morrissey J, Morrissey G, Denning DW Antimicrob Agents Chemother 1998 42 4 873-878
16. 301931 In vitro activity of two echinocandin derivatives LY303366 and MK 0991 (LY-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other antifungal filamentous fungi. Pfaller MA, Marco F, Messer SA, Jones RN Diagn Microbiol Infect Dis 1998 30 4 251-255
17. 308995 Comparison of in vitro activities of the new triazole Sch56592 and the echinocandin MK-0991 (L-743,872) and LY303366 against opportunist filamentous and dimorphic fungi and yeasts. Espinel-Ingroff A J Antimicrob Chemother 1998 36 10 2950-2956 Good review on the antifungal activity of anidulafungin in vitro.
18. 309836 Antifungal efficacy, safety, and single dose plasma pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergilosis in persistently neutropenic rabbits. Petraitis V, Petraitiene R, Groll A, Bell A, Callender DP, Sein T, Schaufele RL, McMillian CL, Bacher J, Walsh TJ Antimicrob Agents Chemother 1998 42 11 2898-2905
19. 309837 In vitro activity of echinocandin antifungal agent LY303366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Oakley KL, Moore CB, Denning DW Antimicrob Agents Chemother 1998 42 10 2726-2730
20. 309838 Susceptibilities of Candida species isolated from the lower gastrointestinal tract of high-risk patients to the new semisynthetic echinocandin LY303366 and other antifungal agents. Zhanel GG, Karlowsky JA, Zelenitsky SA, Turik MA, Hoban DJ Antimicrob Agents Chemother 1998 42 9 2446-2448
21. 326653 Versicor to license antifungal compound from Lilly. Eli Lilly & Co Press Release 1999 June 02
22. 344070 Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Petriatiene R, Petraitis V, Groll AH, Candelario M, Sein T, Bell A, Lyman CA, McMillian CL, Bacher J, Walsh TJ Antimicrob Agents Chemother 1999 43 9 2148-2155
23. 369517 Postantifungal effects of echinocandin, azole and plyene antifungal agents against Candida albicans and Cryptococcus neoformans. Ernst EJ, Klepser ME, Pfaller MA Antimicrob Agents Chemother 2000 44 4 1108-1111
24. 369530 New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Chiou CC, Groll AH, Walsh TJ Oncologist 2000 5 2 120-135
25. 373435 Toxicity of LY 303366, an echinocandin antifungal in mice pretreated with glucocorticoids. Clemons K, Sobel RA, Stevens DA Antimicrob Agents Chemother 2000 44 2 378-381
26. 382521 Phase I dose optimisation study for V-echinocandin. Brown GL, White RJ, Taubel J ICAAC 2000 40 Abs 1105
27. 382524 Phase II, randomised open label study of two intravenous dosing regimens of V-echinocandin in the treatment of esophageal candidiasis. Brown GL, White RJ, Turik M ICAAC 2000 40 Abs 1106
28. 382672 Versicor announces positive phase I and phase II data for novel antifungal and antibacterial agents. Versicor Inc Press Release 2000 September 18
29. 383509 Versicor V-echinocandin vs fluconazole phase III planned for 2001. FDC Reports Pink Sheet 2000 62 39 11
30. 389139 Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (nikkomycin Z) for inhibition and killing of fungal pathogens. Stevens DA Antimicrob Agents Chemother 2000 44 9 2547-2548
31. 402733 Versicor begins pivotal phase III trial with novel antifungal V-echinocandin for treatment of esophageal candidiasis. Versicor Inc Press Release 2001 March 22
32. 412192 American Society for Microbiology - 101st General Meeting, Orlando, FL, USA. IDdb Author IDDB Meeting Report 2001 May 20-24
33. 415095 Efficacy of two new antifungal agents, the triazole ravuconazole and the echinocandin LY 303366, in an experimental model of invasive aspergillosis. Roberts J, Schock K, Marino S, Andriole VT Antimicrob Agents Chemother 2000 44 12 3381-3388
34. 421053 Anidulafungin: Pharmacokinetics in subjects with mild and moderate hepatic impairment. Thye D, Kilfoil T, White RJ, Lasseter K ICAAC 2001 41 Abs 34
35. 421054 Anidulafungin does not affect the metabolism of cyclosporin by human hepatic microsomes. White RJ, Thye D ICAAC 2001 41 Abs 35
36. 421055 Anidulafungin: A phase I study to identify the maximum tolerated dose in healthy volunteers. Thye D, Shepherd B, White RJ, Weston IE, Henkel T ICAAC 2001 41 Abs 36
37. 435010 Versicor begins phase III clinical trial with lead investigational agent, anidulafungin, for invasive aspergillosis. Versicor Inc Press Release 2002 January 07
38. 463845 Tolerance and fugicidality in vitro of caspofungin, micafungin and anidulafungin against Candida guilliermondii. Moore CB, Denning DW ICAAC 2001 42 Abs M230
39. 464527 Anidulafungin: Pharmacokinetics in subjects receiving hemodialysis. Thye D, Marbury T, Kilfoil T, Kilfoil G, Henkel T ICAAC 2001 42 Abs A1390
40. 464528 Anidulafungin: Pharmacokinetics in subjects with renal impairment. Thye D, Marbury T, Kilfoil T, Kilfoil G, Henkel T ICAAC 2001 42 Abs A1391
41. 464529 Anidulafungin: Pharmacokinetics (PK) in subjects with severe hepatic impairment (HI). Thye D, Kilfoil G, Kilfoil T, Henkel T ICAAC 2001 42 Abs A1392
42. 464787 Anidulafungin: Safety and pharmacokinetics in subjects receiving concomitant cyclosporine. Thye D, Kilfoil G, Henkel T ICAAC 2001 42 Abs A1836
43. 466088 Versicor announces completion of pivotal phase III study of anidulafungin for esophageal candidiasis. Versicor Inc Press Release 2002 October 07
44. 475513 Versicor announces positive phase II results with anidulafungin for invasive candidiasis/candidemia. Versicor Inc Press Release 2003 January 06
45. 475615 JP Morgan Hambrecht & Quist - 21st Annual Healthcare Conference (Part I) - Overnight Report, San Francisco, CA, USA. Croasdell G IDDB Meeting Report 2003 January 06-09
46. 476295 Versicor and Biosearch Italia - Creating a transatlantic business with a robust pipeline and complementary distribution strategies in Europe and the US. Versicor Inc Company Presentation 2003 1-28
47. 476443 Clinical efficacy of echinocandin antifungals. Arathoon EG Curr Opin Infect Dis 2001 14 6 685-691 An exhaustive review of all echinocandins, including anidulafungin. Includes in vitro activity and in vivo studies as well as tolerability and pharmacokinetic data of these molecules.
48. 476447 The echinocandins, first novel class of antifungals in two decades: Will they live up to their promise? Graybill JR Int J Clin Pract 2001 55 9 633-638
49. 476451 Pharmacokinetic and pharmacodynamic modelling of anidulafungin (LY 303366): Reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Groll AH, Mickiene D, Petraitiene R, Petraitis V, Lyman CA, Bacher JS, Piscitelli SC, Walsh TJ Antimicrob Agents Chemother 2001 45 10 2845-2855
50. 476453 Regional dependent intestinal absorption and meal composition effects on systemic availability of LY 303366, a lypopeptide antifungal agent, in dogs. Li C, Fleisher D, Li L, Schwier JR, Sweetana SA, Vasudevan V, Zornes LL, Pao LH, Zhou SY, Stratford RE J Pharm Sciences 2001 90 1 47-57 An informative study clarifying the oral bioavailability of anidulafungin.
51. 476454 Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole resistant oropharyngeal and esophageal candidiasis. Petraitis V, Petraitiene R, Groll A, Sein T, Schaufele RL, Lyman CA, Francesconi A, Bacher J, Piscitelli SC, Walsh TJ Antimicrob Agents Chemother 2001 45 2 471-479
52. 482310 Versicor announces positive phase III clinical trial results with anidulafungin for esophageal candidiasis. Versicor Inc Press Release 2003 March 17
53. 487514 Vicuron submits New Drug Application for anidulafungin to FDA. Vicuron Pharmaceuticals Inc Press Release 2003 April 28
54. 489343 Anidulafungin dosage adjustments are not required for patients with hepatic and/or renal impairment. Dowell J, Stogniew M, Krause D Clin Microbiol Infect 2003 9 1 P1222
55. 489454 Vicuron announces positive phase II data with anidulafungin in most common hospital fungal infections presented at ECCMID Meeting. Vicuron Pharmaceuticals Inc Press Release 2003 May 13
56. 490115 Anidulafungin biotransformation in humans is by degradation not metabolism. Stogniew M, Pu F, Henkel T, Dowell J J Clin Microbiol Infect 2003 9 1 P1223
57. 490377 A phase 2 dose-ranging study of the safety and efficacy of anidulafungin in invasive candidiasis. Krause D, Goldstein B, Wible M, Kilfoil G, Henkel T Clin Microbiol Infect 2003 9 1 O403
58. 495130 Vicuron Pharmaceuticals announces FDA acceptance for review of anidulafungin new drug application. Vicuron Pharmaceuticals Inc Press Release 2003 June 30
59. 499803 In vitro activity of voriconazole (UK 109,496), LY 303366 and other antifungal agents against oral Candida spp isolates from HIV infected patients. Chavez M, Bernal S, Valverde A, Gutierrez MJ, Quindos G, Martin-Mazuelos E J Antimicrob Chemother 1999 44 5 697-670 Good overview of the antifungal activity of anidulafungin in vitro against Candida spp and in comparison with other compounds.
60. 499814 In vitro activity of voriconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Serrano MC, Valverde A, Chavez MM, Bernal S, Claro RM, Peman J, Ramirez M, Martin-Mazuelos E Diagn Microbiol Infect Dis 2003 45 2 131-135
61. 499817 Antifungal activities of fluconazole, caspofungin (MK 0991), and anidulafungin (LY 303366) alone and in combination against Candida spp and Cryptococcus neoformans via time-kill methods. Roling EE, Klepser ME, Wasson A, Lewis RE, Ernst EJ, Pfaller MA Diagn Microbiol Infect Dis 2002 43 1 13-17
62. 500098 Antifungal activity of the echinocandin anidulafungin (VER002,LY303366) against yeast pathogens: A comparative study with M27-A microdilution method. Arevalo P, Carrillo-Muñoz AJ, Salgado J, Cardenes D, Brio S, Quindos G, Espinel-Ingroff A J Antimicrob Chemother 2003 51 1 163-166
63. 500128 Caspofungin: The first representative of a new antifungal class. Letscher-Bru V, Herbrecht R J Antimicrob Chemother 2003 51 3 513-521
64. 500223 Revisiting anidulafungin; Final phase III data expected this month. Fortis Bank 2003 March 05